// App-Quantinova.ai

3938 : Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways

Researchers

Presenter

  • Anieta M. Sieuwerts

Principal Investigators

  • Marcel Smid

  • Marcia A. Inda

  • John A. Foekens

  • Anja van de Stolpe

  • John W.M. Martens

  • Wim F.J. Verhaegh

Medical Centers

  • Erasmus MC, Rotterdam, Netherlands

  • Philips Research Eindhoven, Eindhoven, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved